Zhijun Zhou

Zhijun Zhou

Auto-generated profile, based on publicly available information

Zhijun Zhou

Department of Medicine, The University of Oklahoma Health Campus, Oklahoma City, Oklahoma

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 June 2021 in Oncogene
Verified
Journal Article
Open access
PDF file
ZXZhen Xiang
Zhen Xiang
ZZZhijun Zhou
Zhijun Zhou
SSShuzheng Song
Shuzheng Song
JLJun Li
Jun Li
JJJun Ji
Jun Ji
YYYingyan Yu
Yingyan Yu
T cell exhaustion plays critical roles in tumor immune evasion. Novel strategies to suppress immune evasion are in urgent need. We aimed to identify potential compounds to target T cell exhaustion and increase response to immune checkpoint inhibitors (ICIs). Differentially expressed genes (DEGs) were identified between tumors with different immune evasion potential by comparing the transcriptome data. DEGs were then analyzed in the Connectivity Map (CMap) platform to identify potential compounds to increase response to ICIs. Gene set enrichment analysis, LDH release assay, Chromatin immunoprecipitation (ChIP), and Co-IP were performed to explore the potential mechanisms in vitro. Patients derived organoids and humanized xenograft mouse model were utilized to validate the finding ex vivo and in vivo. We identified 25 potential compounds that may play critical roles in regulating tumor immune evasion. We further pinpointed a specific compound, dexamethasone, which shows potent anti-tumor effect in multiple cancer cell lines when cocultured with T cells. Dexamethasone can suppress T cell exhaustion by decreasing the activity of two immune checkpoints simultaneously, including PD-L1 and IDO1. Functional study shows dexamethasone can increase the sensitivity of ICIs in coculture system, 3D organoid model and humanized mouse model. Mechanism study shows dexamethasone mediated transcriptional suppression of PD-L1 and IDO1 depends on the nuclear translocation of GR/STAT3 complex. These findings demonstrate dexamethasone can suppress immune evasion by inducing GR/STAT3 mediated downregulation of PD-L1 and IDO1 pathways.

12 August 2021 in Cancer Research
Verified
Journal Article
Open access
PDF file
QHQiangsheng Hu
Qiangsheng Hu
YQYi Qin
Yi Qin
SJShunrong Ji
Shunrong Ji
XSXiuhui Shi
Xiuhui Shi
WDWeixing Dai
Weixing Dai
XXXiaowu Xu
Xiaowu Xu
Methylthioadenosine phosphorylase (MTAP) is a key enzyme associated with the salvage of methionine and adenine that is deficient in 20% to 30% of pancreatic cancer. Our previous study revealed that MTAP deficiency indicates a poor prognosis for patients with pancreatic ductal adenocarcinoma (PDAC). In this study, bioinformatics analysis of The Cancer Genome Atlas (TCGA) data indicated that PDACs with MTAP deficiency display a signature of elevated glycolysis. Metabolomics studies showed that that MTAP deletion–mediated metabolic reprogramming enhanced glycolysis and de novo purine synthesis in pancreatic cancer cells. Western blot analysis revealed that MTAP knockout stabilized hypoxia-inducible factor 1α (HIF1α) protein via posttranslational phosphorylation. RIO kinase 1 (RIOK1), a downstream kinase upregulated in MTAP-deficient cells, interacted with and phosphorylated HIF1α to regulate its stability. In vitro experiments demonstrated that the glycolysis inhibitor 2-deoxy-d-glucose (2-DG) and the de novo purine synthesis inhibitor l-alanosine synergized to kill MTAP-deficient pancreatic cancer cells. Collectively, these results reveal that MTAP deficiency drives pancreatic cancer progression by inducing metabolic reprogramming, providing a novel target and therapeutic strategy for treating MTAP-deficient disease. Significance: This study demonstrates that MTAP status impacts glucose and purine metabolism, thus identifying multiple novel treatment options against MTAP-deficient pancreatic cancer.

14 December 2022 in Oncogene
Verified
Journal Article
Closed access
PDF file
TYTianfu Yu
Tianfu Yu
FZFengqi Zhou
Fengqi Zhou
WTWei Tian
Wei Tian
RXRan Xu
Ran Xu
BWBinbin Wang
Binbin Wang
JZJunxi Zhang
Junxi Zhang

1 November 2021 in Cancer Letters
Verified
Journal Article
Closed access
YJYuanyuan Jiang
Yuanyuan Jiang
HZHanxiang Zhan
Hanxiang Zhan
YZYuqing Zhang
Yuqing Zhang
JYJingxuan Yang
Jingxuan Yang
MLMingyang Liu
Mingyang Liu
MLMin Li
Min Li

28 November 2023 in Cancer Letters
Verified
Journal Article
Closed access
HWHan Wang
Han Wang
ZZZhijun Zhou
Zhijun Zhou
JZJunchang Zhang
Junchang Zhang
THTengfei Hao
Tengfei Hao
PWPengliang Wang
Pengliang Wang
SYSongcheng Yin
Songcheng Yin

22 July 2025 in Cancer Research Communications
Verified
Journal Article
Open access
ZZZhijun Zhou
Zhijun Zhou
YCYang Cai
Yang Cai
HYHao Yuan
Hao Yuan
QCQun Chen
Qun Chen
SZSophia W. Zhao
Sophia W. Zhao
MLMin Li
Min Li
Immunotherapy has revolutionized the treatment paradigms of several cancer types, yet only a subset of patients derived durable clinical benefit. Ferroptosis is a programmed cell death facilitated by iron-driven overload of lipid peroxidation. We aimed to evaluate ferroptosis activity based on tumor transcriptomic profiles to determine its predictive value for immunotherapy outcomes. We analyzed RNA-sequencing data from eight independent cohorts of patients with urothelial, gastric, skin and lung cancers treated with immune checkpoint inhibitors or adoptive T cell therapy. A ferroptosis activity model was constructed using downstream gene expression signatures. Associations with overall survival (OS) and progression-free survival (PFS) were assessed. Potential mechanisms were explored by examining immunosenescence, interferon-γ immune response pathway and immunogenic cell death. Ferroptosis-high tumors were associated with significantly improved OS and PFS across multiple cancer types. Integrating ferroptosis scores with tumor mutation burden (TMB), liver metastasis status, and immune microenvironment phenotypes (inflamed, excluded, desert) enhanced patient stratification and predictive accuracy. Mechanistically, ferroptosis enhanced immune response by promoting immunogenic cell death and attenuating immunosenescence. In conclusion, elevated ferroptosis activity correlates with improved immunotherapy outcomes, potentially through increased tumor immunogenicity and reduced immunosenescence. Ferroptosis-based biomarkers may aid in identifying patients more likely to benefit from immunotherapy.